clinical trial · NCT06304103
A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome
Myelodysplastic SyndromesAND017
brief summary
This is a Phase 2, multicenter, randomized, open-lable, dose ranging study to evaluate the efficacy and safety of AND017 for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS) in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB).
started
Mar 14, 2025
primary completion
Dec 1, 2026
completion
May 1, 2027
last updated
Feb 27, 2026
official title
An Efficacy and Safety Study of AND017 for the Treatment of Anemia Due to Lower Risk Myelodysplastic Syndromes (MDS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol